GeneDx (WGS) Stock Price, News & Analysis

Company Overview

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care. In 2015, the company became a subsidiary of OPKO Health, leveraging OPKO’s global infrastructure to expand its testing capabilities and research collaborations. GeneDx holds College of American Pathologists (CAP) accreditation and is CLIA-certified, ensuring adherence to stringent quality and regulatory standards.

GeneDx serves a diverse client base that includes hospitals, academic medical centers, reference laboratories and pharmaceutical partners, as well as patients participating in research studies. While its primary market is the United States, the company also accommodates international referrals through its global network, enabling access to advanced genetic diagnostics for clinicians and patients worldwide. With a dedicated team of geneticists, laboratory scientists and genetic counselors, GeneDx continues to advance precision medicine by translating complex genomic data into actionable clinical insights.

Key Stats

• Today's Range: $112.39 to $118.17
• 50-Day Range: $79.83 to $132.54
• 52-Week Range: $44.16 to $136.00
• Volume: 566,116 shs
• Average Volume: 499,593 shs
• Market Capitalization: $3.37 billion
• P/E Ratio: 2,347.40
• Dividend Yield: N/A
• Price Target: $104.13
• Consensus Rating: Moderate Buy

GeneDx Stock Analysis - MarketRank™

GeneDx scored higher than 51% of companies evaluated by MarketBeat, and ranked 586th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

GeneDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.

Downside Risk

GeneDx has a consensus price target of $104.13, representing about 11.3% downside from its current price of $117.37.

Amount of Analyst Coverage

GeneDx has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 115.46%

Earnings Growth

Earnings for GeneDx are expected to grow by 115.46% in the coming year, from $0.97 to $2.09 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GeneDx is 2,347.40, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 281.79.

Price to Earnings Ratio vs. Sector

The P/E ratio of GeneDx is 2,347.40, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 76.39.

Price to Book Value per Share Ratio

GeneDx has a P/B Ratio of 13.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.35% of the float of GeneDx has been sold short.

Short Interest Ratio / Days to Cover

GeneDx has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in GeneDx has recently decreased by 0.55%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GeneDx does not currently pay a dividend.

Dividend Growth

GeneDx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

14.35% of the float of GeneDx has been sold short.

Short Interest Ratio / Days to Cover

GeneDx has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in GeneDx has recently decreased by 0.55%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.93

News Sentiment

GeneDx has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for GeneDx this week, compared to 12 articles on an average week.

Search Interest

9 people have searched for WGS on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.

MarketBeat Follows

5 people have added GeneDx to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, GeneDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $68,279,628.00 in company stock.

Percentage Held by Insiders

29.60% of the stock of GeneDx is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

61.72% of the stock of GeneDx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

WGS Stock Analysis - Frequently Asked Questions

How have WGS shares performed this year?

GeneDx's stock was trading at $76.86 at the start of the year. Since then, WGS stock has increased by 52.7% and is now trading at $117.37.

How were GeneDx's earnings last quarter?

GeneDx Holdings Corp. (NASDAQ:WGS) released its earnings results on Tuesday, July, 29th. The company reported $0.50 EPS for the quarter, topping analysts' consensus estimates of $0.10 by $0.40. The firm earned $102.69 million during the quarter, compared to the consensus estimate of $86 million. GeneDx had a trailing twelve-month return on equity of 16.51% and a net margin of 0.39%.
Read the conference call transcript.

When did GeneDx's stock split?

GeneDx's stock reverse split on Thursday, May 4th 2023.The 1-33 reverse split was announced on Thursday, May 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of GeneDx?

Shares of WGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of GeneDx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GeneDx investors own include Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

• Last Earnings: 7/29/2025
• Today: 10/02/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:WGS
• CIK: 1818331
• Web: sema4.com
• Phone: 800-298-6470
• Fax: N/A
• Employees: 1,200
• Year Founded: 2000

Price Target and Rating

• Average Price Target for GeneDx: $104.13
• High Price Target: $140.00
• Low Price Target: $80.00
• Potential Upside/Downside: -11.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.05
• Trailing P/E Ratio: 2,347.40
• Forward P/E Ratio: 121.00
• P/E Growth: N/A
• Net Income: -$52.29 million
• Net Margins: 0.39%
• Pretax Margin: 0.42%
• Return on Equity: 16.51%
• Return on Assets: 9.35%

Debt

• Debt-to-Equity Ratio: 0.19
• Current Ratio: 2.87
• Quick Ratio: 2.70

Sales & Book Value

• Annual Sales: $362.32 million
• Price / Sales: 9.31
• Cash Flow: $1.06 per share
• Price / Cash Flow: 110.86
• Book Value: $8.75 per share
• Price / Book: 13.41

Miscellaneous

• Outstanding Shares: 28,726,000
• Free Float: 20,223,000
• Market Cap: $3.37 billion
• Optionable: Optionable
• Beta: 1.99